News & Events

bluebird bio and Celgene are collaborating to develop CAR T cell therapies targeting BCMA.

bluebird bio and Celgene announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.

Inception Neuroscience Program Acquired by Roche

The acquisition is the culmination of a June 2014 alliance between Inception and Roche to discover and develop novel small molecules that promote remyelination of nerve fibers damaged during the progression of multiple sclerosis.

Pfizer abandoned Alzheimer’s and Parkinson’s research

Pfizer, the world’s third largest drug maker, has announced it is ending research to discover new medications for Alzheimer’s and Parkinson’s disease

Novartis: ‘Time is right’ for $13bn consumer health sale to GSK

As part of an asset exchange in 2014​, Novartis and GlaxoSmithKline (GSK) combined their over-the-counter (OTC) drugs and nutritional supplements businesses to form a consumer health joint venture.

World’s first commercial iPS cell-making plant opens.

A new facility of Sumitomo Dainippon Pharma Co. in Suita, Osaka Prefecture, to culture and treat induced pluripotent stem (iPS) cells to produce cells for medical use

A deal potentially worth over 900 million euros ($1.1 billion) for Prexton Therapeutics, biotech start-up located since inception at Eclosion’s premises at Plan-les-Ouates

H. Lundbeck A/S and Prexton Therapeutics BV announced signing of a definitive agreement in which Lundbeck will acquire Prexton

Stop the heating! Cold can activate body’s ‘good’ fat at a cellular level, study finds

Lower temperatures can activate the body’s ‘good’ fat formation at a cellular level, a new study led by academics at The University of Nottingham has found.

Could drugs used after an organ transplant protect against Alzheimer’s?

A UT Southwestern study in mice provides new clues about how a class of anti-rejection drugs used after organ transplants may also slow the progression of early-stage Alzheimer’s disease.

Get in touch

Subscribe to Eclosion Newsletter


© 2016 Fondation Eclosion
All rights reserved
Webdesign: Comstone / Pierre Chassany
WordPress Development: Olivier Gisiger